• Adefovir Pharmacokinetics in an OAT1 Cocktail

  2026-09-24

  A population pharmacokinetic reanalysis of 24 healthy volunteers found that co-administration in a transporter cocktail altered apparent adefovir bioavailability and absorption rate, but not renal elimination. The findings support renal clearance as a practical OAT1 phenotyping measure at the tested doses, while emphasizing that the observed interaction likely arose before or during systemic appearance of adefovir.

• DNase I (RNase-free) for RNA QC

  2026-09-24

  Use ribonuclease-free DNase I to remove residual DNA from RNA extraction and in vitro transcription samples before reverse-transcription assays. Paired with suitable controls and cleanup, this step helps distinguish DNA carryover from genuine RNA quality signals—an important consideration when assessing long self-amplifying RNA by ddPCR.

• ERAD Hijacking Enables Degradation of Membrane Proteins

  2026-09-23

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a targeted protein degradation strategy that recruits endoplasmic reticulum-associated degradation machinery to degrade transmembrane proteins. Their PD-L1 results and identification of desonide as a SYVN1-binding degrader component establish a promising platform, while leaving important questions about selectivity, mechanism, and therapeutic translation for further study.

• LY294002 for Reliable PI3K Assays

  2026-09-23

  Learn how LY294002 (SKU A8250) can improve interpretation of cell viability, proliferation, apoptosis, and autophagy experiments through controlled PI3K/Akt/mTOR pathway inhibition. This scenario-based guide covers mechanism, solvent compatibility, dose selection, data interpretation, and practical product-selection criteria.

• Live-Dead Cell Staining Kit: Assay Workflow

  2026-09-22

  Build a quantitative cell viability assay around Calcein-AM and Propidium Iodide to distinguish intact, membrane-compromised, and treatment-affected cells. This workflow shows how the dual stain can support flow cytometry, fluorescence microscopy, biomaterial testing, and drug cytotoxicity testing while avoiding common interpretation errors.

• Targeting Fructose Metabolism in Cancer: Key Insights

  2026-09-22

  The 2025 Cancer Letters review frames fructose metabolism as a coordinated driver of tumor bioenergetics, signaling, immune suppression, and malignancy rather than simply an alternative nutrient pathway. Its synthesis supports biomarker-guided studies of GLUT5, KHK, AKR1B1, and related metabolic nodes while emphasizing that epidemiologic associations still require mechanistic and clinical validation.

• Arginine Methylation, FUS, and Neuronal Granules

  2026-09-21

  Wang and Li show that asymmetric dimethylation of FUS does more than regulate its homotypic phase behavior: it creates binding sites for oligomeric SMN and promotes multivalent condensate formation. Their results connect this molecular mechanism to neuronal granule assembly, axonal mRNA distribution, and SMN-linked defects relevant to spinal muscular atrophy.

• SM-102 (C1042) for Reliable LNP Viability Assays

  2026-09-21

  This scenario-based guide shows how SM-102 (SKU C1042) can support more interpretable cell viability, proliferation, and cytotoxicity studies involving mRNA lipid nanoparticles. It connects formulation handling, assay controls, mechanistic evidence, and supplier-selection criteria without overstating viability or delivery performance.

• Carbon-Ion Radiotherapy, Ferroptosis, and DHODH

  2026-09-20

  A 2025 study links carbon-ion radiotherapy with DHODH suppression, ferroptosis-related changes, and M1-like macrophage polarization in gastric cancer models. Its findings suggest that DHODH may influence both tumor-cell stress responses and radiation-associated immune signaling, although validation in immunocompetent and clinically representative systems remains necessary.

• SARS-CoV-2 PLpro Regulation of ER Proteins

  2026-09-19

  This study shows that membrane-anchored SARS-CoV-2 papain-like protease (PLpro) regulates endoplasmic reticulum proteins through two catalytic activities: deubiquitination and proteolytic cleavage. Its substrate-dependent effects on INSIG-1, SREBP-1, and SREBP-2 reveal how viral PLpro may alter ER-associated degradation and lipid-regulatory pathways.

• HIV-1 Protease Autoprocessing in High-Throughput Screening

  2026-09-18

  Huang and colleagues developed a validated cell-based AlphaLISA assay that measures HIV-1 protease precursor autoprocessing rather than only mature protease activity. The platform selectively recognized known HIV protease inhibitors, supported resistance assessment, and provided a practical framework for screening compounds that are simultaneously cell permeable, non-toxic, and active against an early viral maturation step.

• Intestinal TM6SF2 and the Gut–Liver Axis in MASH

  2026-09-18

  This reference study shows that intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis by maintaining epithelial barrier function and constraining microbiota- and lipid-driven signaling. Its genetic, microbiota-transfer, and pharmacological experiments connect intestinal TM6SF2 loss with pathobiont enrichment, lysophosphatidic acid transport, hepatic lipid accumulation, and inflammation.

• CapK–CapS: DNA Damage Control of Bacterial Immunity

  2026-09-17

  The reference study identifies CapK and CapS as a DNA damage-responsive kinase–repressor pair that controls bacterial immune operon expression. Its findings connect repair-associated single-stranded DNA sensing to CapS phosphorylation, transcriptional de-repression, and activation of immune or toxin–antitoxin defenses.

• TopBP1 Inhibition Enhances PARP Blockade

  2026-09-17

  Lin and colleagues developed CS18, a structurally distinct inhibitor of the TopBP1 BRCT7/8 interaction surface, using docking-guided screening and structure–activity optimization. The study shows that disrupting oncogenic TopBP1 complexes can induce apoptosis and mitotic catastrophe, enhance PARP inhibitor activity, and restore osimertinib sensitivity in resistant EGFR-mutated lung cancer models.

• Cisplatin (CDDP) Workflow for Apoptosis Studies

  2026-09-16

  Build reproducible Cisplatin workflows for DNA-damage, apoptosis, oxidative-stress, and chemotherapy resistance studies. Learn how to adapt a cisplatin-induced ovarian granulosa cell model to exosome rescue experiments, viability testing, and mechanistic validation.

8447 records 1/564 page Next 12345 下5页 Last page